

BK

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
25 October 2001 (25.10.2001)

PCT

(10) International Publication Number
WO 01/78735 A1

- (51) International Patent Classification⁷: **A61K 31/565**, 31/165, A61P 11/00 // (A61K 31/565, 31:165) (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (21) International Application Number: PCT/GB01/01656
- (22) International Filing Date: 12 April 2001 (12.04.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
0009046.4 13 April 2000 (13.04.2000) GB
0105967.4 10 March 2001 (10.03.2001) GB
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
-
- (71) Applicant (*for all designated States except US*): INNOVATA BIOMED LIMITED [GB/GB]; The Ziggurat, Grosvenor Road, St. Albans AL1 3HW (GB).
- (72) Inventor; and
- (75) Inventor/Applicant (*for US only*): SANDERS, Mark [GB/GB]; The Ziggurat, Grosvenor Road, St Albans AL1 3HW (GB).
- (74) Agent: HARRISON GODDARD FOOTE; Tower House, Merrion Way, Leeds LS2 8PA (GB).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/78735 A1

(54) Title: MEDICAMENTS FOR TREATING RESPIRATORY DISORDERS COMPRISING FORMOTEROL AND FLUTICASONE

(57) Abstract: There is described a method of treating or alleviating a respiratory disorder which comprises administering an effective amount of the active ingredients formoterol, or a pharmaceutically acceptable salt thereof, and fluticasone, or a pharmaceutically acceptable ester thereof, separately, sequentially or simultaneously, provided that the active ingredients comprise separate compositions. There is also described a dry powder inhaler containing formoterol, or a pharmaceutically acceptable salt thereof, and fluticasone, or a pharmaceutically acceptable ester thereof, which may be administered separately, sequentially or simultaneously, provided that they are administered as separate compositions.

Medicaments

This invention relates to a novel method of treatment and to a novel use of known medicaments.

5

Formoterol or N-[2-hydroxy-5-[1-hydroxy-2-[[2- (4-methoxyphenyl)-1- methylethyl] amino]ethyl]-phenyl] formamide is known from British Patent No 1415256. Formoterol is a β -adrenoreceptor agonist which has antiasthmatic properties and selective bronchodilator properties.

10

Fluticasone or S-fluoromethyl 6α , 9α -difluoro- 11β -hydroxy- 16α -methyl- 17α -hydroxy-3-oxoandrosta-1,4-diene- 17β -carbothioate is an anti-inflammatory corticosteroid with minimal liability to undesired systemic side effects which is described in British Patent No 2088877.

15

Numerous attempts have been made at preparing efficacious combination therapies. Thus, a combination therapy of fluticasone, i.e. fluticasone propionate, and a bronchodilator, namely salmeterol, is known from US Patent No 5,270,305. Furthermore, European Patent Application No. 9202826 describes formoterol and budesonide combinations and European Patent No 0 416 951 describes salmeterol and fluticasone combinations.

20

However, each of these combination therapies suffers from certain disadvantages, *inter alia*, they may be unsuitable for use in the treatment or alleviation of acute asthma symptoms or may not be optimal for the treatment of the inflammatory component of the disease .

25

More recently, International Patent Application No. WO 00/48587, Clarke *et al*, which is an intervening publication, published on 1 November 2000, describes a pharmaceutical composition comprising formoterol fumarate and fluticasone propionate which as being useful in the treatment of inflammatory or obstructive airways disease.

30

We have now surprisingly found that a combination of formoterol, or a salt thereof, and fluticasone, or an ester thereof, can be therapeutically effective if the medicaments are administered separately, sequentially or simultaneously, provided
5 that such administration comprises separate compositions of the two active ingredients. The administration of a combination of fluticasone, or a pharmaceutically acceptable ester thereof, and formoterol, or a pharmaceutically acceptable salt thereof, separately, sequentially or simultaneously is advantageous in that it is more efficacious than other prior art combination therapies.

10

Thus, according to the invention we provide a method of treating or alleviating a respiratory disorder which comprises administering an effective amount of the active ingredients formoterol, or a pharmaceutically acceptable salt thereof, and fluticasone, or a pharmaceutically acceptable ester thereof, separately, sequentially or
15 simultaneously, provided that the active ingredients comprise separate compositions.

20

According to a further embodiment, the method of the invention comprises the separate or sequential administration of formoterol, or a pharmaceutically acceptable salt thereof, and fluticasone, or a pharmaceutically acceptable ester thereof.

In an alternatively preferred embodiment the method of the invention comprises the separate administration of formoterol, or a salt thereof, and fluticasone, or an ester thereof.

25 In an especially preferred embodiment the method of the invention comprises the sequential administration of formoterol, or a salt thereof, and fluticasone, or an ester thereof.

In an alternatively preferred embodiment the method of the invention comprises the
30 separate administration of formoterol, or a salt thereof, and fluticasone, or an ester thereof.

When the method of the invention comprises the sequential administration of the active ingredients, it is preferred that the method comprises the administration of formoterol, or a salt thereof, followed by the sequential administration of fluticasone, or an ester thereof.

The method of the invention is most advantageous in the treatment of respiratory disorders such as asthma and/or chronic obstructive pulmonary disease (COPD).

10 In the method of the invention the formoterol, or a salt thereof, and the fluticasone, or an ester thereof, may be administered in a variety of ways but the most preferred method of administration is by way of inhalation. Thus, the method of the invention may comprise administration by way of an inhaler, e.g. a metered dose inhaler or a dry powder inhaler, an insufflator, a nebuliser or any other conventionally known method of administering inhalable medicaments.

When administered by way of inhalation the method of the invention may comprise the use of a pressurised aerosol.

20 Thus, according to a further feature of the invention we provide a method which comprises administration by way of a pressurised aerosol comprising, separately, formoterol, or a salt thereof, and formoterol, or an ester, as hereinbefore described, each being in admixture with at least a suitable propellant and optionally with a surfactant or a mixture of surfactants. The propellant is preferably a non-CFC propellant, such as a hydrofluoroalkane (HFA). Any conventionally known HFA propellant may be used, including those disclosed in, for example, EP0372777, WO91/04011, WO91/11173, WO91/11495 and WO91/14422. However, the most preferred HFA is a fluoroalkane such as a fluoromethane or a fluoroethane or a mixture of fluoroalkanes. Such fluoroalkanes include, but are not limited to, 25 trichlorofluoromethane, dichlorodifluoromethane, 1,2-dichlorotetrafluoroethane, trichlorotrifluoroethane and chloropentafluoroethane. The most preferred is HFA 30

134 (1,1,1,2-tetrafluoroethane) or HFA 227. The amount of propellant present may vary, but generally the active ingredient to propellant ratio will be from 1 to 300 to 1 to 5. Mixtures of propellants may also be used, for example, a mixture of HFA 134 and HFA 227. Thus the aerosol compositions of the invention may be as a solution
5 or a suspension each of the active ingredients with a propellant.

The pressurised aerosol formulations of the invention may be administered in any conventionally known inhalation apparatus.

10 In another embodiment the method may comprise administration of the active ingredients as dry powder formulations. Thus, according to the invention we provide a method as hereinbefore described which comprises administration by way of a dry powder inhaler wherein the inhaler comprises, separately, formoterol, or a salt thereof, and fluticasone, or an ester thereof, each, optionally in admixture with a
15 suitable adjuvant, diluent or carrier.

The dry powder formulations of the invention may be administered in any conventionally known inhalation apparatus. However, such a dry powder inhaler comprising, separately, formoterol, or a salt thereof, and fluticasone, or an ester thereof, is novel *per se*.
20

Thus, according to a further feature of the invention we provide a dry powder inhaler containing formoterol, or a pharmaceutically acceptable salt thereof, and fluticasone, or a pharmaceutically acceptable ester thereof.
25

Each of the active ingredients may optionally be in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.

Any conventionally used ingredients in dry powder formulations may be used, as
30 suitable adjuvant, diluent or carrier such as sugars, these include, but are not limited

to, dextran, mannitol and lactose, e.g. α -lactose monohydrate. Preferably, the active ingredient to carrier ratio is from 0.001 : 1 to 50 : 1, for example, 0.4% w/w.

In a dry powder inhaler the formoterol, or a pharmaceutically acceptable salt thereof,
5 and the fluticasone, or a pharmaceutically acceptable ester thereof, may be administered separately, sequentially or simultaneously, provided that the active ingredients comprise separate compositions.

Preferred dry powder inhalers are those described in our co-pending Patent
10 application No. PCT/GB 00/03377 or PCT/GB 00/04623.

Alternatively, the formulations may be administered by way of a conventional nebuliser. A suitable nebuliser formulation consists of a sterile, isotonic solution of the pharmaceutical compositions of the invention in water, optionally containing one
15 or more surfactants or a pharmaceutically acceptable co-solvent. Alternatively, the nebuliser formulation may comprise a suspension of the pharmaceutical compositions of the invention in finely divided form in a sterile isotonic solution. The solution or suspension may be nebulised by an air jet, dropping onto an ultrasonic vibrating plate, forcing through small orifices or other known types of
20 nebuliser, including unit-dose nebulisers, including those described by Dolovich, M., "New Propellant-free Technologies under Investigation", J. Aerosol Medicine, 1999; 12 (suppl 1): S9-S17, such as, Respimat (from Boehringer Ingelheim), AERx™ (from Aradigm), and AeroDose (from Aerogen).

25 For inhalation therapy the active ingredients are preferably micronised or reduced in size by other recognised mechanisms, such as spray drying, co-milling, etc. The particle size of the fluticasone, or a pharmaceutically acceptable ester thereof, and the formoterol, or a pharmaceutically acceptable salt thereof, may be the same or different. However, it is preferred that both fluticasone, or a pharmaceutically
30 acceptable ester thereof, and formoterol, or a pharmaceutically acceptable salt thereof, will have an aerodynamic particle size of from 1 to 10 microns.

The dosage of each of the active ingredients administered to a patient may vary depending, *inter alia*, upon the nature and severity of the disorder being treated and the method of administration.

5

In a preferred embodiment, each metered dose or actuation of an inhaler will generally contain from 3 μg to 50 μg of formoterol, or a pharmaceutically acceptable salt thereof, and from 20 μg to 500 μg of fluticasone, or a pharmaceutically acceptable ester thereof. The frequency of administration of each of the active
10 ingredients may vary, but most preferably, each of the active ingredients will be administered, separately, sequentially or simultaneously, but as separate compositions, once or twice daily, although other treatment regimes may be applicable.

15 According to a further feature of the invention we provide a method of treating COPD which comprises administering to a patient suffering from such a disorder a therapeutically effective amount of formoterol, or a pharmaceutically acceptable salt thereof, and formoterol, or a pharmaceutically acceptable ester thereof, separately,
sequentially or simultaneously, provided that if the active ingredients are
20 administered simultaneously, they are as separate compositions.

We also provide the use of fluticasone, or a pharmaceutically acceptable ester thereof, in the manufacture of a medicament for use in the method as hereinbefore described.

25

We further provide the use of formoterol, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament as hereinbefore described.

We also provide the use of formoterol, or a salt thereof, and fluticasone, or an ester
30 thereof, in the manufacture of a dry powder inhaler as hereinbefore described.

According to a further feature of the invention we provide the use of formoterol, or a pharmaceutically acceptable salt thereof, and fluticasone, or a pharmaceutically acceptable ester thereof, as active ingredients in the manufacture of a medicament to be administered separately, sequentially or simultaneously, provided that the active ingredients comprise separate compositions for the treatment or alleviation of a respiratory disorder.

It is known that glucocorticoids are used for the suppression of inflammation in chronic inflammatory diseases which are associated with an increase in the expression of inflammatory genes (cytokines, enzymes, receptors and adhesion molecules). This is thought to be due in part to a direct inhibitory interaction between activated glucocorticoid receptors and activated transcription factors which results in regulation of the inflammatory gene expression. In this mechanism the inhibitory effect of the glucocorticoid on cytokine synthesis is considered to be of particular importance. It has also been found that glucocorticoids increase the expression of β_2 adrenoreceptors by increasing the rate of transcription of the human β_2 receptors.

Thus known combination therapies can be expected to be efficacious, but we have surprisingly found that the new therapy of the invention is especially advantageous in that tests indicate, *inter alia*, a significant increase in glucocorticoid receptor translocation to the nucleus and in immunocomplex formation.

Therefore according to a yet further feature of the invention we provide a method of attaining improved glucocorticoid receptor translocation into the nucleus (and the functional consequences, for example on cytokine expression) by the administration of a therapeutically effective amount of a β_2 agonist and a steroid in therapeutically effective amounts wherein the method provides an improvement of at least 20%, preferably at least 35%, over prior art β_2 agonist and a steroid combination therapies.

In this particular feature of the invention the preferred method comprises the administration of therapeutically effective amounts of formoterol and fluticasone. The method may comprise an improvement of from 35 – 50% over known combination therapies.

5

Thus when measured as a change in density on a Western Blot strip, the method of this aspect of the invention may provide a percentage change in band density of at least 255, preferably of at least 300, for example, between 300 and 400 percentage change in band density.

10

This particular aspect of the invention is advantageous in that it may be useful in providing more efficacious therapies in a variety of inflammatory disorders, for example, asthma, rheumatoid arthritis, inflammatory bowel disease and autoimmune diseases.

15

According to a further feature of the invention we provide the use of a glucocorticoid, e.g. fluticasone, in the manufacture of a medicament with improved β_2 receptor expression.

20 In this aspect of the invention the improved β_2 receptor expression may be an improvement of at least 20% over prior art medicaments, preferably at least 35%, for example, from 35 – 50%.

25 Thus when measured as a change in density on a Western Blot strip, we provide the use of a glucocorticoid in the manufacture of a medicament with improved β_2 receptor expression measured as a percentage change in band density of at least 255, preferably of at least 300, for example, between 300 and 400 percentage change in band density.

The ratio of formoterol, or a pharmaceutically acceptable salt thereof, to fluticasone, or a pharmaceutically acceptable ester thereof, in the method of the invention may vary, but is preferably within the range from 1 : 0.4 to 1 : 167.

- 5 Suitable pharmaceutically acceptable salts of formoterol include acid addition salts derived from inorganic and organic acids, such as the hydrochloride, hydrobromide, sulphate, phosphate, maleate, tartrate, citrate, benzoate, 4-methoxybenzoate, 2- or 4-hydroxybenzoate, 4-chlorobenzoate, p-toluenesulphonate, methanesulphonate, ascorbate, salicylate, acetate, fumarate, succinate, lactate, glutarate, gluconate,
10 hydroxynaphthalenecarboxylate e.g. 1-hydroxy- or 3-hydroxy-2-naphthalenecarboxylate, or oleate. The fumarate salt is especially preferred.

- The formoterol, or a pharmaceutically acceptable salt thereof, may be present either as a racemic mixture, as a mixture of enantiomers or substantially as a single D- or L-
15 isomer.

- Suitable pharmaceutically acceptable esters of fluticasone include alkanoates, e.g. C₁ to C₁₀ alkanoates, preferably C₁ to C₅ alkanoates. The propionate ester is especially preferred.
20

The invention will now be described by way of example only and with reference to the accompanying drawings in which references to fluticasone are to fluticasone propionate and references to formoterol are references formoterol fumarate.

- 25 Figure 1 is a representation of Western Blot strip following the assay of Example 1; and

Figure 2 is a bar chart based on the Western Blot of Figure 1.

Example 1

30

Western blot analysis

Nuclear and cytosolic proteins were extracted from U937 cells by gentle detergent lysis. Cells were lysed for 15 minutes at 4°C using 0.1% NP-40 and cytoplasmic proteins collected. Soluble nuclear extracts were obtained following osmotic lysis (0.42 M NaCl) of the nuclear envelope. At least 20 µg/lane of whole-cell proteins were subjected to a 10% SDS-polyacrylamide gel electrophoresis, and transferred to nitrocellulose filters (Hybond-ECL, Amersham Pharmacia Biotech, Amersham, UK) by blotting. Filters were blocked for 1h at room temperature in Tris-buffered saline (TBS), 0.05% Tween 20, 5% non-fat dry milk. The filters were then incubated with rabbit anti-human GR antibody (Santa Cruz Biotechnology, Santa Cruz, CA) for 1h at room temperature in PBS, 0.05% Tween 20, 5% non-fat dry milk at dilution of 1:1000. Filters were washed three times in PBS, 0.05% Tween 20 and after incubating for 45 minutes at room temperature with anti-rabbit antibody conjugated to horseradish peroxidase (Dako, Ely, UK) in PBS, 0.05% Tween 20 and 5% non-fat dry milk, at dilution of 1:4000. After further three washes in PBS with 0.05% Tween 20 visualisation of the immunocomplexes was performed using ECL (see Figure 1) as recommended by the manufacturer (Amersham Pharmacia Biotech).

The bands, which were visualised at approximately 94 kDa, were quantified using a densitometer with Grab-It and GelWorks software (UVP, Cambridge, UK) (see Figure 2). The percentage change in band density is therefore proportional to increase in glucocorticoid receptor translocation into the nucleus

The results are given in Table 1.

Table 1

Composition	% Change in Band Density
Control	100 ± 0
Formoterol	197 ± 18
Salmeterol	183 ± 12

Budesonide/Fluticasone	142 ± 8
Salmeterol/Fluticasone	231 ± 26
Formoterol/Fluticasone	312 ± 26
Formoterol/Budesonide	197 ± 10
Salmeterol/Budesonide	183 ± 24

Example 2

5 Oedema Model Studies

Tests were performed to determine the effect of formoterol and fluticasone on the inhibition of lung inflammation. The test model employed was the Sephadex-induced oedema model.

10

Sephadex was administered intratracheally to Sprague-Dawley rats together with saline (control), formoterol, fluticasone, salmeterol, formoterol-fluticasone combinations, budesonide-fluticasone combinations, fluticasone-salmeterol combinations, budesonide-formoterol combinations and budesonide-salmeterol combinations. Animals were subjected to each relevant experimental regimen and were then sacrificed, their lungs excised and the inflammatory process measured as lung weight increase due to oedema.

15

The weight increase of lungs removed from animals subjected to the Sephadex-saline regimen compared to the weight of lungs removed from a second group of control animals, to which only saline was administered and this taken as maximum Sephadex induced oedema.

20

Inhibition of the Sephadex induced lung oedema by a test substance was determined as a percentage reduction of induced oedema in the presence of the test compound compared to the maximum oedema induced in the Sephadex-saline controls.

25

Example 3**Separate/Sequential Administration of Formoterol and Fluticasone**

- 5 The experiments of Examples 1 and 2 were repeated using a dosing regimen comprising the separate and/or sequential administration of formoterol and fluticasone and experiments were extended to include determination of the functional consequence of the increase in receptor translocation on pro- and anti-inflammatory cytokine expression, including TNF alpha, interleukin 10, GM-CSF and interleukin 1 -receptor antagonist.

10

15

20

25

30

35

40

CLAIMS

1. A method of treating or alleviating a respiratory disorder which comprises administering an effective amount of the active ingredients formoterol, or a
5 pharmaceutically acceptable salt thereof, and fluticasone, or a pharmaceutically acceptable ester thereof, separately, sequentially or simultaneously, provided that the active ingredients comprise separate compositions.
2. A method according to claim 1 characterised in that the formoterol, or a
10 pharmaceutically acceptable salt thereof, and the fluticasone, or a pharmaceutically acceptable ester thereof, are administered separately or sequentially.

3. A method according to claim 2 characterised in that the formoterol, or a
15 pharmaceutically acceptable salt thereof, and the fluticasone, or a pharmaceutically acceptable ester thereof, are administered sequentially.
4. A method according to claim 3 characterised in that the method comprises the administration of fluticasone, or a pharmaceutically acceptable ester thereof, followed by the sequential administration of formoterol, or a pharmaceutically
20 acceptable salt thereof.
5. A method according to claim 2 characterised in that the formoterol, or a
25 pharmaceutically acceptable salt thereof, and fluticasone, or a pharmaceutically acceptable ester thereof, are delivered separately.
6. A method according to claim 1 characterised in that the formoterol, or a
pharmaceutically acceptable salt thereof, and fluticasone, or a pharmaceutically acceptable ester thereof, are administered by inhalation.
- 30 7. A method according to claim 6 characterised in that the formoterol, or a pharmaceutically acceptable salt thereof, and the fluticasone, or a pharmaceutically

acceptable ester thereof, are administered by way of pressurised aerosols comprising a pharmaceutical composition in admixture with at least a suitable propellant.

- 5
8. A method according to claim 7 in which a surfactant is present.
9. A method according to claim 8 in which a surfactant is absent.
10. A method according to claim 9 characterised in that the surfactant is a mixture of surfactants.
- 10
11. A method according to claim 7 characterised in that the propellant, or mixture of propellants, is a non-CFC propellant.
-
12. A method according to claim 11 characterised in that the propellant, or
- 15 mixture of propellants, is selected from hydrofluoroalkanes (HFA).
13. A method according to claim 12 characterised in that the propellant is HFA
- 134.
- 20 14. A method according to claim 12 characterised in that the propellant is HFA
- 227.
15. A method according to claim 12 characterised in that the propellant is a mixture of HFA 134 and HFA 227.
- 25
16. A method according to claim 6 characterised in that the formoterol, or a pharmaceutically acceptable salt thereof, and the fluticasone, or a pharmaceutically acceptable ester thereof, are administered by way of a dry powder inhaler.
- 30 17. A dry powder inhaler containing formoterol, or a pharmaceutically acceptable salt thereof, and fluticasone, or a pharmaceutically acceptable ester thereof, which

may be administered separately, sequentially or simultaneously, provided that they are administered as separate compositions.

18. A dry powder inhaler according to claim 15 comprising formoterol, or a pharmaceutically acceptable salt thereof, and fluticasone, or a pharmaceutically acceptable ester thereof, each in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.
19. A dry powder inhaler according to claim 16 characterised in that the adjuvant, diluent or carrier is selected from dextran, mannitol and lactose.
-
20. A dry powder inhaler according to claim 17 characterised in that the carrier is lactose.
21. A dry powder inhaler according to claim 17 characterised in that the dry powder inhaler is selected from those described in PCT/GB 00/04623.
22. A dry powder inhaler according to claim 17 characterised in that the dry powder inhaler is selected from those described in PCT/GB 00/03377.
23. A method according to claim 1 characterised in that the formoterol, or a pharmaceutically acceptable salt thereof, and fluticasone, or a pharmaceutically acceptable ester thereof, are administered by way of a nebuliser comprising a solution or a suspension of formoterol, or a pharmaceutically acceptable salt thereof, and fluticasone, or a pharmaceutically acceptable ester thereof.
24. A method according to Claim 1 characterised in that a the amount of formoterol, or a pharmaceutically acceptable salt thereof, administered to a patient is from 20 to 500 µg and the amount of fluticasone, or a pharmaceutically acceptable ester thereof, administered to a patient is from 3 to 50 µg; once or twice daily.

25. A method according to claim 1 characterised in that the respiratory disorder is COPD.
26. A method according to Claim 1 characterised in that the pharmaceutically acceptable salt of formoterol, is selected from an acid addition salts; hydrochloride, hydrobromide, sulphate, phosphate, maleate, tartrate, citrate, benzoate, 4-methoxybenzoate, 2- or 4-hydroxybenzoate, 4-chlorobenzoate, p-toluenesulphonate, methanesulphonate, ascorbate, salicylate, acetate, fumarate, succinate, lactate, glutarate, gluconate, hydroxynaphthalenecarboxylate and oleate.
27. A method according to claim 26 characterised in that the pharmaceutically acceptable salt of formoterol, is the fumarate salt.
-
28. A method according to claim 1 characterised in that the pharmaceutically acceptable ester of fluticasone, is the propionate ester.
29. A method of attaining improved glucocorticoid receptor translocation into the nucleus by the administration of a therapeutically effective amount of a β_2 agonist and a steroid in therapeutically effective amounts wherein the method provides an improvement of at least 20% over prior art β_2 agonist and steroid combination therapies.
30. The use of formoterol, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the method according to claim 1.
31. The use of fluticasone, or a pharmaceutically acceptable ester thereof, in the manufacture of a medicament for use in the method according to claim 1.
32. The use of formoterol, or a pharmaceutically acceptable salt thereof, and fluticasone, or a pharmaceutically acceptable ester thereof, as active ingredients in the manufacture of a medicament to be administered separately, sequentially or

simultaneously, provided that the active ingredients comprise separate compositions for the treatment or alleviation of a respiratory disorder.

33. The use of a glucocorticoid in the manufacture of a medicament with improved β_2 receptor expression.

34. A method according to Claim 1 characterised in that the ratio of formoterol, or a pharmaceutically acceptable salt thereof, to fluticasone, or a pharmaceutically acceptable ester thereof, is in the range 1 : 0.4 to 1 : 167.

35. A method or an inhaler substantially as described with reference to the accompanying examples.





Fig. 1



n=2

INTERNATIONAL SEARCH REPORT

Int onal Application No

PCT/GB 01/01656

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/565 A61K31/165 A61P11/00 //(A61K31/565,31:165)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, EPO-Internal, PAJ, BIOSIS, CHEM ABS Data, PHARMAPROJECTS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 30262 A (DMITROVIC BOSKO ;BUDAY GOLDBERGER DAVID (FR); SEQUELAS ETIENNE (FR) 16 July 1998 (1998-07-16) *cf. page 4, line 21 bridging with page 5, lines 1-8*	1-35
X	EP 0 938 907 A (GLAXO GROUP LTD) 1 September 1999 (1999-09-01) *cf. abstract, col. 4, lines 8-17*	1-35
X	EP 0 534 731 A (FISONS PLC) 31 March 1993 (1993-03-31) *cf. abstract, page 3, lines 25-31*	1-35
X	EP 0 979 661 A (GLAXO WELLCOME LAB) 16 February 2000 (2000-02-16) *cf. col. 4, lines 14-29*	1-35
	--- -/-	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

10 August 2001

Date of mailing of the international search report

03/09/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Stoltner, A

Int: onal Application No
PCT/GB 01/01656

Int: onal Application No
PCT/GB 01/01656

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 709 884 A (BRIGGNER LARS-ERIK ET AL) 20 January 1998 (1998-01-20) *cf. col. 7, claim 4*	1-35
Y	WO 94 13271 A (ASTRA AB) 23 June 1994 (1994-06-23) *cf. page 1, lines 1-19	1-35
Y	US 5 873 359 A (FROSTELL CLAES ET AL) 23 February 1999 (1999-02-23) *cf. col. 1, lines 40-47, col. 6, lines 57-65*	1-35

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 01/01656

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9830262 A	16-07-1998	AU 735126 B	28-06-2001
		AU 6207298 A	03-08-1998
		BR 9806864 A	18-04-2000
		CN 1249694 T	05-04-2000
		CZ 20000298 A	17-05-2000
		EP 0954348 A	10-11-1999
		HR 980382 A	31-10-1999
		HU 0000885 A	28-08-2000
		NO 993348 A	07-07-1999
		PL 334447 A	28-02-2000
		TR 9901582 T	21-09-1999
		TR 200000032 T	21-07-2000
		TW 404843 B	11-09-2000
EP 0938907 A	01-09-1999	AU 725348 B	12-10-2000
		AU 1163397 A	01-08-1997
		BR 9612410 A	13-07-1999
		CA 2241880 A	17-07-1997
		CN 1213974 A	14-04-1999
		CZ 9802125 A	11-11-1998
		EP 0883414 A	16-12-1998
		WO 9725086 A	17-07-1997
		JP 2000503565 T	28-03-2000
		NO 983069 A	03-09-1998
EP 0534731 A	31-03-1993	NZ 324374 A	29-06-1999
		NZ 334058 A	29-06-1999
		PL 327616 A	21-12-1998
		TR 9801265 T	21-10-1998
		TR 9900235 T	21-04-1999
		US 6065472 A	23-05-2000
		HU 9904274 A	28-04-2000
		AT 132739 T	15-01-1996
		AU 654397 B	03-11-1994
		AU 2647192 A	27-04-1993
		BG 61752 B	29-05-1998
		BG 98681 A	28-02-1995
		BR 1100446 A	18-04-2000
		BR 9206549 A	17-10-1995
		CA 2119932 A	01-04-1993
		CN 1071832 A, B	12-05-1993
		CZ 9400695 A	15-11-1995
		DE 69207606 D	22-02-1996
		DE 69207606 T	27-06-1996
		DK 605578 T	25-03-1996
		EP 0605578 A	13-07-1994
		ES 2082507 T	16-03-1996
		FI 941388 A	25-03-1994
		WO 9305765 A	01-04-1993
		GR 3019098 T	31-05-1996
		GR 3032103 T	31-03-2000
		HK 1005564 A	15-01-1999
		HU 67480 A	28-04-1995
		HU 210818 B	28-08-1995
		IL 103238 A	31-07-1995
		JP 7502262 T	09-03-1995
		JP 3142136 B	07-03-2001
		MX 9205483 A	01-05-1993

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 01/01656

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0534731 A		NO 941077 A	18-05-1994
		NZ 244439 A	26-01-1994
		RO 114735 B	30-07-1999
		RU 2122852 C	10-12-1998
		SK 34094 A	09-11-1994
		US 6123924 A	26-09-2000
		ZA 9207242 A	22-03-1993
EP 0979661 A	16-02-2000	AU 710027 B	09-09-1999
		AU 3567095 A	29-03-1996
		BR 9508935 A	06-01-1998
		CA 2199858 A	21-03-1996
		WO 9608284 A	21-03-1996
		EP 0835146 A	15-04-1998
		FI 971101 A	14-03-1997
		HU 77459 A,B	28-04-1998
		IL 115298 A	26-07-2000
		JP 10505764 T	09-06-1998
		NO 971207 A	14-05-1997
		NZ 293269 A	28-07-1998
		US 6220243 B	24-04-2001
		US 6065471 A	23-05-2000
		ZA 9507723 A	30-07-1996
US 5709884 A	20-01-1998	AT 199828 T	15-04-2001
		AU 681186 B	21-08-1997
		AU 7626494 A	21-03-1995
		BR 9407320 A	16-04-1996
		CN 1133004 A,B	09-10-1996
		CN 1195523 A	14-10-1998
		CZ 9600544 A	15-05-1996
		DE 69426934 D	26-04-2001
		DK 717616 T	11-06-2001
		EE 3203 B	15-04-1996
		EG 20779 A	29-02-2000
		EP 0717616 A	26-06-1996
		ES 2156158 T	16-06-2001
		FI 960869 A	26-02-1996
		HU 74000 A,B	28-10-1996
		JP 2978247 B	15-11-1999
		JP 9501930 T	25-02-1997
		NO 960744 A	23-02-1996
		NZ 273090 A	24-06-1997
		PL 313142 A	10-06-1996
		RU 2148992 C	20-05-2000
		WO 9505805 A	02-03-1995
		SG 47760 A	17-04-1998
		SK 23496 A	05-02-1997
		US 5637620 A	10-06-1997
		US 5874063 A	23-02-1999
		ZA 9405675 A	29-04-1996
WO 9413271 A	23-06-1994	AU 5663494 A	04-07-1994
		CA 2148617 A	23-06-1994
		EP 0673244 A	27-09-1995
		JP 8504438 T	14-05-1996
		US 6250300 B	26-06-2001
		US 5642728 A	01-07-1997

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 01/01656

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9413271 A		US 5934273 A	10-08-1999
US 5873359 A	23-02-1999	AT 158509 T	15-10-1997
		AU 657726 B	23-03-1995
		AU 9149891 A	08-07-1992
		CA 2097823 A	06-06-1992
		DE 69127756 D	30-10-1997
		DE 69127756 T	05-02-1998
		DE 560928 T	22-09-1994
		DE 786264 T	02-11-2000
		DK 560928 T	01-12-1997
		EE 3119 B	15-02-1996
		EP 0560928 A	22-09-1993
		EP 0786264 A	30-07-1997
		ES 2082732 T	01-04-1996
		ES 2132043 T	16-08-1999
		GR 96300032 T	30-06-1996
		GR 3024865 T	30-01-1998
		GR 99300018 T	30-06-1999
		HK 1010101 A	23-06-2000
		JP 10158175 A	16-06-1998
		JP 2701978 B	21-01-1998
		JP 6504778 T	02-06-1994
		LV 12201 A	20-01-1999
		LV 12201 B	20-05-1999
		SG 47527 A	17-04-1998
		US 5536241 A	16-07-1996
		WO 9210228 A	25-06-1992
		US 5570683 A	05-11-1996
		US 5485827 A	23-01-1996